Champions Oncology (NASDAQ:CSBR) & Rapid Micro Biosystems (NASDAQ:RPID) Financial Analysis

Rapid Micro Biosystems (NASDAQ:RPID) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Rapid Micro Biosystems and Champions Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1	0	2	0	2.33
Champions Oncology	1	0	0	0	1.00

Rapid Micro Biosystems currently has a consensus price target of $6.00, suggesting a potential upside of 261.45%. Given Rapid Micro Biosystems’ stronger consensus rating and higher probable upside, research analysts plainly believe Rapid Micro Biosystems is more favorable than Champions Oncology.

Profitability

This table compares Rapid Micro Biosystems and Champions Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%
Champions Oncology	-1.87%	-27.48%	-3.84%

Earnings & Valuation

This table compares Rapid Micro Biosystems and Champions Oncology”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$35.18 million	2.37	-$47.12 million	($1.12)	-1.48
Champions Oncology	$59.42 million	1.16	-$1.17 million	($0.08)	-62.04

Champions Oncology has higher revenue and earnings than Rapid Micro Biosystems. Champions Oncology is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

52.6% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by company insiders. Comparatively, 46.4% of Champions Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Rapid Micro Biosystems has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

About Champions Oncology

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.